Effects of Roflumilast on subclinical atherosclerosis in COPD - a randomized controlled trial

M. Urban (WIEN, Austria)

Source: International Congress 2017 – Extrapulmonary comorbidities in COPD
Session: Extrapulmonary comorbidities in COPD
Session type: Thematic Poster
Number: 693
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
M. Urban (WIEN, Austria). Effects of Roflumilast on subclinical atherosclerosis in COPD - a randomized controlled trial. 693

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
A prospective randomised double-blind placebo controlled trial of venlafaxine in patients with stable chronic obstructive pulmonary disease (COPD)
Source: Eur Respir J 2006; 28: Suppl. 50, 32s
Year: 2006

Can simvastatin reduce COPD exacerbations? A randomised double-blind controlled study
Source: Eur Respir J, 58 (1) 2001798; 10.1183/13993003.01798-2020
Year: 2021



Roflumilast for stable COPD: Meta-analysis of randomized controlled trials
Source: International Congress 2014 – Clinical presentations
Year: 2014


Roflumilast in Asian patients with COPD: A randomised placebo-controlled trial
Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD
Year: 2011

A randomised controlled trial of zafirlukast in acute asthma
Source: Eur Respir J 2005; 26: Suppl. 49, 254s
Year: 2005

Late Breaking Abstract - First-time assessment of efficacy of candidate vaccine to prevent acute exacerbations of chronic obstructive pulmonary disease (AECOPD): multicentre, randomised, controlled, observer-blind phase 2b trial
Source: Virtual Congress 2021 – ALERT: COPD
Year: 2021



ß-blockers in exacerbations of COPD: feasibility of a randomised controlled trial
Source: ERJ Open Res, 3 (1) 00090-2016; 10.1183/23120541.00090-2016
Year: 2017



Pulmonary vasodilator therapy in severe COPD: a double-blind, placebo-controlled trial
Source: Eur Respir J 2007; 30: Suppl. 51, 525s
Year: 2007

A randomised double-blind placebo-controlled trial of the effect of inhaled heparin on lung function, hyperinflation and exercise capacity in patients with COPD
Source: International Congress 2016 – Novel insights into the treatment of COPD
Year: 2016

Effects of a concomitant therapy with Cineole (Eucalyptole) on exacerbation rate in COPD: A placebo-controlled double-blind trial
Source: Annual Congress 2010 - COPD exacerbation
Year: 2010

RCT Abstract - Randomized, double-blind, placebo-controlled, phase III clinical trial with MV130, a sublingual bacterial immunotherapy to prevent COPD exacerbations
Source: Virtual Congress 2021 – ALERT: COPD
Year: 2021



Efficacy of azithromycin in severe asthma from the AMAZES randomised trial
Source: ERJ Open Res, 5 (4) 00056-2019; 10.1183/23120541.00056-2019
Year: 2019



RCT Abstract - Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomized, double-blind, placebo-controlled, phase 3 trial
Source: Virtual Congress 2021 – ALERT: Asthma in adult, in children and ILDs
Year: 2021



Clinical effectiveness of MDI-HFA-Modulite budesonide in the treatment of asthma – meta-analysis of randomised controlled trials
Source: Eur Respir J 2006; 28: Suppl. 50, 315s
Year: 2006

Acute effects of nasal high-flow during exercise in COPD patients after an exacerbation : a randomized controlled cross-over trial
Source: International Congress 2019 – COPD treatment: cardiovascular, oxygen and vaccination studies
Year: 2019

Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial.
Source: Eur Respir J 2002; 20: 245
Year: 2002


Early pulmonary rehabilitation after acute exacerbation of COPD: a randomised controlled trial
Source: ERJ Open Res, 6 (1) 00173-2019; 10.1183/23120541.00173-2019
Year: 2020



Azithromycin for the treatment of cough in idiopathic pulmonary fibrosis: A randomized controlled cross-over pilot trial.
Source: Virtual Congress 2020 – Chronic cough: only symptom or disease?
Year: 2020




Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial
Source: Eur Respir J 2013; 42: 1622-1632
Year: 2013